Telomir Pharmaceuticals, Inc. closed its acquisition of TELI Pharmaceuticals, Inc. on April 22, 2026, making TELI a wholly owned subsidiary. The transaction was structured as a stock‑for‑stock exchange, with Telomir issuing 34,389,710 restricted shares to former TELI shareholders. At closing, Telomir also received $1.0 million in cash and is eligible for up to an additional $4.0 million in milestone‑based contributions tied to regulatory and clinical milestones, such as IND acceptance and the initiation of a Phase 1/2 trial.
The equity consideration values TELI at approximately $101.1 million and Telomir at about $126.8 million, giving TELI shareholders roughly 59 % of the combined entity. The deal eliminates geographic fragmentation of Telomir‑1 (Telomir‑Zn) rights, allowing the company to pursue a unified clinical development program across all regions.
Telomir‑1 is a first‑in‑class metal‑modulating epigenetic agent that restores transcriptional control in tumor cells by targeting intracellular iron‑zinc homeostasis. Preclinical studies show the compound reduces tumor growth and metastasis in triple‑negative breast cancer models and has a favorable safety profile in GLP studies. An IND has been submitted to the FDA for advanced and metastatic triple‑negative breast cancer, positioning the company to move into human trials once regulatory clearance is obtained.
Financially, Telomir remains a preclinical‑stage company with no revenue. However, its cash runway and liquidity are strong, with a current ratio of 5.14 and a GF Score™ of 22, indicating potential profitability challenges but solid short‑term financial health. The acquisition and milestone funding provide additional capital to support the upcoming clinical program without diluting existing shareholders beyond the agreed 59 % ownership stake for former TELI shareholders.
CEO Erez Aminov said the closing “represents a defining milestone for Telomir. By securing worldwide rights to Telomir‑1, we have established a globally unified platform as we advance toward clinical development.” He added that the milestone funding “aligns capital support with clinical progress” and that the deal will enhance partnership opportunities and accelerate the path to market for the first‑in‑class therapy.
The acquisition positions Telomir to streamline regulatory submissions, optimize trial design across regions, and strengthen its competitive stance in the age‑related disease and triple‑negative breast cancer markets. With unified rights and additional milestone funding, the company is better positioned to secure future collaborations and bring Telomir‑1 to patients faster.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.